Effect of silymarin in prevention of adverse effects of anti tuberculosis drugs.

Evaluation of Silymarin in prevention of anti tuberculosis drug induced hepatitis in patients newly diagnosed with tuberculosis.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000621011

Enrollment

Registered

2010-07-29

Start date

2010-08-01

Completion date

2010-11-09

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

One of most important adverse effects of anti tuberculosis drugs is drug induced hepatitis. Adverse effects of drugs are one of causes for treatment interruption. Purpose of this study is prevention or decreasing incidence of drug induced hepatitis.

Interventions

Silymarin 420 mg per day, for the first 2 weeks of anti-tuberculosis treatment, as oral tablets

Study design

Allocation

Randomised controlled trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

New cases of tuberculosis

Exclusion criteria

1. Infection with Human Immune deficiency virus 2. Infection with hepatitis B virus 3. Infection with hepatitis c virus 4. Abnormal liver function tests in the base 5. Patients treated with the regimens other than Isoniazide, Rifampin, Pyrazinamide.

Outcome results